

**RACHEL E. SACHS**  
Washington University School of Law  
Campus Box 1120, One Brookings Drive  
St. Louis, MO 63130  
rsachs@wustl.edu

ACADEMIC APPOINTMENTS

**Washington University in St. Louis**, St. Louis, MO 2016 – Present  
*Wiley B. Rutledge Professor of Law* 2026 – Present  
*Faculty Co-Director, Cordell Institute for Policy in Medicine and Law* 2026 – Present  
*Professor of Public Health (Secondary)* 2025 – Present  
*Professor of Law* 2021 – 2026  
*Treiman Professor of Law* 2021 – 2024  
*Associate Professor of Law* 2016 – 2021

**The Brookings Institution**, Washington, DC 2022 – Present  
*Nonresident Fellow, Schaeffer Initiative for Health Policy*

**NYU School of Law**, New York, NY Spring 2022  
*Visiting Professor of Law*

**Harvard Law School**, Cambridge, MA 2014 – 2016, Fall 2024  
*Academic Fellow, Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics*  
*Lecturer on Law, Spring 2016*  
*Howard J. and Katherine W. Aibel Visiting Professor of Law, Fall 2024*

LAW SCHOOL TEACHING

Property Law, FDA Law, Health Law, Patent Law, Health Law and Access to Medicines (Seminar), Innovation in Pharmaceutical Technologies (Seminar)

EDUCATION

**Harvard Law School**, Cambridge, MA  
*Juris Doctor, magna cum laude*, 2013  
Activities: *Harvard Law Review*, Articles Chair  
Petrie-Flom Center Student Fellow in Health Law Policy, Biotechnology, and Bioethics  
John M. Olin Student Fellow in Law and Economics

**Harvard School of Public Health**, Cambridge, MA  
*Master of Public Health*, 2013  
Internship: United States Department of Health & Human Services, Centers for Medicare & Medicaid Services, Region 1  
Thesis: “The Impact of the Affordable Care Act’s Medicaid Expansion on Region 1”

**Princeton University**, Princeton, NJ  
*Bachelor of Arts* with High Honors in Bioethics, 2009  
Honors: Phi Beta Kappa  
Thesis: “Research Involving Human Biological Materials: Legal and Ethical Issues”

PUBLIC SERVICE

**United States Department of Health and Human Services Office of the General Counsel, Centers for Medicare and Medicaid Services Division**, *Senior Advisor*, April 2023 – April 2024  
Recipient of 2024 HHS Office of the General Counsel “OGC Excellence of Service Group Award”

## JUDICIAL CLERKSHIP

**The Honorable Richard A. Posner, U.S. Court of Appeals for the Seventh Circuit, Chicago, IL**  
*Law Clerk, 2013–2014*

## PUBLICATIONS

### **Law Review Articles**

*Regulating Healthcare Technologies in a Post-FDA World*, NORTHWESTERN U. L. REV. (forthcoming 2026).

*A New Framework for Drug Pricing Law and Policy*, 101 IND. L.J. 389 (2026).

*Venturing Into Health*, 94 FORDHAM L. REV. 131 (2025).

*Rethinking Innovation at FDA* (with W. Nicholson Price II & Patricia J. Zettler), 104 B.U. L. REV. 513 (2024).

*Cryptic Patent Reform Through the Inflation Reduction Act* (with Arti K. Rai & W. Nicholson Price II), 37 HARV. J. L. & TECH. 57 (2024).

*The Accidental Innovation Policymakers*, 72 DUKE L. J. 1431 (2023).

- Reviewed in *Jotwell*, <https://cyber.jotwell.com/congressional-myopia-in-biomedical-innovation-policy/>
- Selected for inclusion in the Junior Faculty Forum for Law and STEM workshop

*The Role of State Attorneys General in Improving Prescription Drug Affordability* (with Michelle Mello & Trish Riley), 95 S. CAL. L. REV. 595 (2022).

*New Innovation Models in Medical AI* (with W. Nicholson Price II & Rebecca S. Eisenberg), 99 WASH. U. L. REV. 1121 (2022).

*Integrating Health Innovation Policy*, 34 HARV. J. L. & TECH. 57 (2020).

*The Medicare Innovation Subsidy* (with Mark Lemley & Lisa Larrimore Ouellette), 95 NYU L. REV. 75 (2020).

- Reviewed in *Jotwell*, <https://health.jotwell.com/medicare-reimbursement-for-prescription-drugs-an-overlooked-policy-lever-for-innovation/>

*Regulating Intermediate Technologies*, 37 YALE J. REG. 219 (2020).

*The Uneasy Case for Patent Law*, 117 MICH. L. REV. 499 (2018).

- Selected for inclusion in the Junior Faculty Forum for Law and STEM workshop
- Selected for inclusion in the BioIP junior faculty workshop

*Delinking Reimbursement*, 102 MINN. L. REV. 2307 (2018).

- Solicited for inclusion in the Law Review's 2017 Symposium
- Selected as one of the ten "Notable Employee Benefits Articles of 2018" by TAX NOTES

*Administering Health Innovation*, 39 CARDOZO L. REV. 1991 (2018).

- Selected for inclusion in the Health Law Scholars Workshop at St. Louis University School of Law
- Selected as one of eight finalists in the American Association of Law Schools' Scholarly Papers competition

*Prizing Insurance: Prescription Drug Insurance as Innovation Incentive*, 30 HARV. J. L. & TECH. 153 (2016).

- Reviewed in *Jotwell*, <https://health.jotwell.com/health-insurance-as-innovation-incentive/>

*Innovation Law and Policy: Preserving the Future of Personalized Medicine*, 49 U.C. DAVIS L. REV. 1881 (2016).

Rachel E. Sachs & Carolyn A. Edelstein, *Ensuring the Safe and Effective FDA Regulation of Fecal Microbiota Transplantation*, 2 J. L. & BIOSCIENCES 396 (2015) (peer reviewed).

*The New Model of Interest Group Representation in Patent Law*, 16 YALE J. L. & TECH. 344 (2014).

Anthony D. So & Rachel Sachs, *Making Intellectual Property Work for Global Health*, 53 HARV. INT'L L.J. ONLINE 106 (2012).

### **Shorter Pieces in Law Reviews**

*Evaluating the Case Against FDA Independence* (with Patricia J. Zettler), UTAH L. REV. (forthcoming 2026) (invited).

*Competitive Concerns from Pharmacy Benefit Managers Selling Their Own Drugs* (with Michael A. Carrier), 24 YALE J. HEALTH POL'Y L. & ETHICS 71 (2026).

*Encouraging Interagency Collaboration: Learning from COVID-19*, 4 J.L. & INNOVATION 71 (2021) (invited).

*Judge Posner's Reconstruction of Property Theory*, 86 U. CHI. L. REV. 1201 (2019) (invited).

*Addressing Pharmaceutical Price Spikes Through Generic Preclearance*, 39 J. LEGAL MEDICINE 169 (2019) (invited).

*Review of I CONTAIN MULTITUDES*, J. L. & BIOSCIENCES (2017).

*Mobile Health Innovation and Interagency Coordination*, 26 ANNALS OF HEALTH LAW 1 (2017).

*Prizes for Payers*, J. L. & BIOSCIENCES (2017) (peer reviewed) (invited commentary on Rebecca S. Eisenberg & W. Nicholson Price, II, *Promoting Healthcare Innovation on the Demand Side*, J. L. & BIOSCIENCES (2017)).

Note, *Diagnostic Method Patents and Harms to Follow-On Innovation*, 126 HARV. L. REV. 1370 (2013).

The Supreme Court, 2011 Term—Leading Case, *Mayo Collaborative Services v. Prometheus Laboratories, Inc.*, 126 HARV. L. REV. 347 (2012).

Recent Case, *Federal Circuit Invalidates Diagnostic Method Claims as Drawn to "Abstract Mental Processes"*: *Association for Molecular Pathology v. U.S. Patent & Trademark Office*, 125 HARV. L. REV. 658 (2011).

### **Peer-Reviewed Journals**

Rachel E. Sachs & Kristi Martin, *CMS' GLP-1 Bridge Demonstration – Questions and Potential Consequences*, J. AM. MED. ASS'N (published online ahead of print June 24, 2026).

Luca Maini, Rachel E. Sachs, Michael Anne Kyle, & Pragya Kakani, *Medicaid's GENEROUS Most-Favored-Nation Pricing Model – Promise and Limitations*, 394 NEW ENG. J. MED. 1772 (2026).

Adrianna McIntyre, Michael Anne Kyle, & Rachel E. Sachs, *Rural Health Transformation Program: Trends in Projected Scores and Actual Awards*, HEALTH AFFAIRS SCHOLAR (published online ahead of print March 24, 2026).

- Rachel E. Sachs, Stacie B. Dusetzina, & Aaron P. Mitchell, *Biosimilar Competition in Oncology – Beyond Insurer Pressure*, 335 J. AM. MED. ASS'N 1217 (2026).
- Aaron P. Mitchell, Rachel E. Sachs, & Stacie B. Dusetzina, *Oncology Drug Revenue and Price Negotiation*, 12 J. AM. MED. ASS'N ONCOLOGY 139 (2026).
- Stacie B. Dusetzina & Rachel E. Sachs, *Insurance Coverage and Pricing of Weight-Loss Drugs in the United States*, 394 NEW ENG. J. MED. 105 (2025).
- Hayden Rooke-Ley & Rachel E. Sachs, *Pharmaceutical Wholesalers – Under-the-Radar Middlemen?*, 393 NEW ENG. J. MED. 1358 (2025).
- Rachel E. Sachs, Thomas J. Hwang, & Stacie B Dusetzina, *The Role of Combination Drugs in the Medicare Drug Price Negotiation Program*, 334 J. AM. MED. ASS'N 759 (2025).
- Rachel E. Sachs & Allison K. Hoffman, *The Changing Role of the Government in American Health Law*, 50 J. HEALTH POLITICS, POL'Y, & L. 1017 (2025).
- Rachel E. Sachs, Joshua M. Sharfstein, & Patricia J. Zettler, *Judicial Invalidation of the FDA's Laboratory-Developed Test Rule – Legal and Public Health Consequences*, 392 NEW ENG. J. MED. e49 (2025).
- Patricia J. Zettler, Rachel E. Sachs, Steven Joffe, & Holly Fernandez Lynch, *The Dangers of Decoupling Safety and Effectiveness in Drug Approval*, 333 J. AM. MED. ASS'N 1765 (2025).
- Rachel E. Sachs & Richard G. Frank, *Assessing the Effect of the Medicare Part D Redesign*, 333 J. AM. MED. ASS'N 663 (2025).
- Rachel E. Sachs & Erin C. Fuse Brown, *Supreme Power – The Loss of Judicial Deference to Health Agencies*, 391 NEW ENG. J. MED. 777 (2024).
- Steven Joffe, Rena M. Conti, Jorge L. Contreras, Emily A. Largent, Holly Fernandez Lynch, David Mitchell, Rachel E. Sachs, Allison M. Whelan & Matthew S. McCoy, *Access to Affordable Medicines: Obligations of Universities and Academic Medical Centers*, 30 GENE THERAPY 753 (2023).
- Shelley A. Jazowski, Avi U. Vaidya, Julie M. Donohue, Stacie B. Dusetzina, & Rachel E. Sachs, *Commercial Health Plan and Enrollee Out-of-Pocket Spending on Accelerated Approval Products in 2019*, 183 J. AM. MED. ASS'N INTERNAL MEDICINE 1016 (2023).
- Rachel E. Sachs, Loren Adler, & Richard Frank, *A Holistic View of Innovation Incentives and Pharmaceutical Policy Reform*, HEALTH AFFAIRS SCHOLAR doi:10.1093/haschl/qxad004 (published online July 2023).
- Holly Fernandez Lynch, Rachel E. Sachs, Sejin Lee, Matthew Herder, Joseph S. Ross, & Reshma Ramachandran, *Extending the US Food and Drug Administration's Postmarket Authorities*, 4 J. AM. MED. ASS'N HEALTH FORUM e231313 (2023).
- Shelley A. Jazowski, Avi U. Vaidya, Julie M. Donohue, Stacie B. Dusetzina, & Rachel E. Sachs, *Time to Confirmatory Study Initiation After Accelerated Approval of Cancer and Noncancer Drugs in the US*, 183 J. AM. MED. ASS'N INTERNAL MEDICINE 737 (2023).
- Holly Fernandez Lynch & Rachel E. Sachs, *Preapproval Promises to Voluntarily Withdraw FDA-Approved Drugs*, 328 J. AM. MED. ASS'N 2392 (2022).
- Rachel E. Sachs, Julie M. Donohue, & Stacie B. Dusetzina, *Reforming Reimbursement for the US Food and Drug Administration's Accelerated Approval Program to Support State Medicaid Programs*, 11 J. AM. MED. ASS'N HEALTH FORUM e224115 (2022).

Rachel E. Sachs, Shelley A. Jazowski, Kyle A. Gavulic, Julie M. Donohue, & Stacie B. Dusetzina, *Medicaid and Accelerated Approval: Spending on Drugs with and without Proven Clinical Benefits*, 47 J. HEALTH POLITICS, POL'Y, & L. 673 (2022).

Rachel E. Sachs, Julie M. Donohue, & Stacie B. Dusetzina, *Accelerated Approval – Taking the FDA's Concerns Seriously*, 387 NEW ENG. J. MED. 199 (2022).

Rachel E. Sachs & Michael Anne Kyle, *Step Therapy's Balancing Act – Protecting Patients While Addressing High Drug Prices*, 386 NEW ENG. J. MED. 901 (2022).

Rachel E. Sachs, Kyle A. Gavulic, Julie M. Donohue, & Stacie B. Dusetzina, *Changes in the Use of Hydroxyprogesterone Caproate Injection After Confirmatory Trial Failure*, 182 J. AM. MED. ASS'N INTERNAL MEDICINE 226 (2022).

Rachel E. Sachs & Nicholas Bagley, *Medicare Coverage of Aducanumab – Implications for State Budgets*, 385 NEW ENG. J. MED. 2019 (2021).

Rachel E. Sachs, Kyle A. Gavulic, Julie M. Donohue, & Stacie B. Dusetzina, *Recent Trends in Medicaid Spending and Use of Drugs with US Food and Drug Administration Accelerated Approval*, 10 J. AM. MED. ASS'N HEALTH FORUM e213177 (2021).

Rachel E. Sachs, *The Rhetorical Transformations and Policy Failures of Prescription Drug Pricing Reform Under the Trump Administration*, 46 J. HEALTH POLITICS, POL'Y, & L. 1053 (2021).

Rachel E. Sachs, Julie M. Donohue, & Stacie B. Dusetzina, *Confronting State Medicaid Drug Spending Pressures*, 324 J. AM. MED. ASS'N 1831 (2020).

Rachel E. Sachs & Adam Sacarny, *Ensuring Access to Emerging COVID-19 Treatments Through Medicare Reimbursement Policy*, J. AM. MED. ASS'N HEALTH FORUM (Aug. 7, 2020), <https://jamanetwork.com/channels/health-forum/fullarticle/2769378>.

Rachel E. Sachs & Nicholas Bagley, *Importing Prescription Drugs from Canada – Legal and Practical Problems with the Trump Administration's Proposal*, 382 NEW ENG. J. MED. 1777 (2020).

Rena Conti, Stacie B. Dusetzina, & Rachel Sachs, *How the ACA Reframed the Prescription Drug Market and Set the Stage for Current Reform Efforts*, 39 HEALTH AFFAIRS 445 (2020).

Thomas J. Hwang, Kerstin N. Vokinger, & Rachel E. Sachs, *Evaluating New Rules on Transparency in Cancer Research and Drug Development*, 5 J. AM. MED. ASS'N ONCOLOGY 461 (2019).

Austin Frakt & Rachel E. Sachs, *A Smarter Way to Provide Epinephrine at School*, 173 J. AM. MED. ASS'N PEDIATRICS 130 (2019).

Peter B. Bach & Rachel E. Sachs, *Expansion of the Medicare 340B Payment Program: Hospital Participation, Prescribing Patterns and Reimbursement, and Legal Challenges*, 320 J. AM. MED. ASS'N 2311 (2018).

Nicholas Bagley & Rachel E. Sachs, *Limiting State Flexibility in Drug Pricing*, 379 NEW ENG. J. MED. 1002 (2018).

Rachel E. Sachs, Nicholas Bagley, & Darius N. Lakdawalla, *Innovative Contracting for Pharmaceuticals and Medicaid's Best-Price Rule*, 43 J. HEALTH POLITICS, POL'Y, & L. 5 (2018).

Rachel E. Sachs, Paul B. Ginsburg, & Dana P. Goldman, *Encouraging New Uses for Old Drugs*, 318 J. AM. MED. ASS'N 2421 (2017).

Thomas J. Hwang, Rachel E. Sachs, & Aaron S. Kesselheim, *Public Participation in Drafting of the 21<sup>st</sup> Century Cures Act*, 45 J. L. MED. & ETHICS 212 (2017).

Amitabh Chandra & Rachel E. Sachs, *An FDA Commissioner for the 21<sup>st</sup> Century*, 376 NEW ENG. J. MED. e31 (2017).

Rachel E. Sachs & Austin B. Frakt, *Innovation-Innovation Tradeoffs in Drug Pricing*, 165 ANNALS OF INTERNAL MEDICINE 871 (2016).

### **Book Chapters**

*Innovation Law and COVID-19: Promoting Incentives and Access for New Healthcare Technologies* (with Lisa Larrimore Ouellette, Nicholson Price, & Jacob Sherkow), in COVID-19 AND THE LAW: DISRUPTION, IMPACT AND LEGACY (eds. I. Glenn Cohen, Abbe Gluck, Katherine Kraschel, & Carmel Shachar) (Cambridge University Press 2023).

*The Impact of the ACA on the Debate Over Drug Pricing Regulation* (with Steven D. Pearson), in THE TRILLION DOLLAR REVOLUTION: HOW THE AFFORDABLE CARE ACT TRANSFORMED POLITICS, LAW, AND HEALTH CARE IN AMERICA (eds. Ezekiel J. Emanuel & Abbe R. Gluck) (PublicAffairs 2020).

*Increasing FDA Transparency as Enhancing the Innovation Process* (with Thomas J. Hwang), in TRANSPARENCY IN HEALTH AND HEALTH CARE (eds. I. Glenn Cohen, Barbara Evans, & Holly Fernandez Lynch) (Cambridge University Press 2019).

*Introduction: Intellectual Property Rights for Health Big Data*, in BIG DATA, HEALTH LAW, AND BIOETHICS (eds. I. Glenn Cohen, Holly Fernandez Lynch, Effy Vayena, & Urs Gasser) (Cambridge University Press 2018).

*Human Tissue Samples: Balancing Autonomy vs. Justice* (with David E. Korn), in SPECIMEN SCIENCE: ETHICS AND POLICY IMPLICATIONS (eds. Barbara E. Bierer, I. Glenn Cohen, Holly Fernandez Lynch, & Suzanne M. Rivera) (MIT Press 2017).

*Religious Exemptions to the Individual Mandate: Health Care Sharing Ministries and the Affordable Care Act*, in LAW, RELIGION, AND HEALTH IN AMERICA (eds. I. Glenn Cohen, Holly Fernandez Lynch, & Elizabeth Sepper) (Cambridge University Press 2017).

### **Invited Legislative Testimony (Selected)**

Testimony before the United States House of Representatives Committee on Energy & Commerce, Subcommittee on Health, Hearing on Lowering Health Care Costs for All Americans: An Examination of the Prescription Drug Supply Chain, February 11, 2026.

Testimony before the United States Senate Committee on the Judiciary, Hearing on Reducing Prescription Drug Prices: How Competition Can Make Medications Affordable for Patients, October 29, 2024.

Testimony before the United States House of Representatives Committee on Energy & Commerce, Subcommittee on Health, Hearing on Negotiating a Better Deal: Legislation to Lower the Cost of Prescription Drugs, May 4, 2021.

Testimony before the United States House of Representatives Committee on Ways & Means, Hearing on the Cost of Rising Prescription Drug Prices, February 12, 2019.

### **Additional Online Publications (Selected)**

Over 100 contributions at:

- *Bill of Health*, <https://blogs.harvard.edu/billofhealth/author/rachelsachs/>

- These contributions have been cited in briefs before the United States Court of Appeals for the Federal Circuit, as well as letters from Congressional Committees.
- *Health Affairs Forefront*, <https://www.healthaffairs.org/doi/10.1377/hauthor20150409.379586>
  - These pieces have been cited in reports and letters from Congressional Committees.
- *STAT*, <https://www.statnews.com/category/the-regulars/analysis-rachel-sachs/>
- *Written Description*, <https://writtendescription.blogspot.com/>

*International Reference Pricing for Prescription Drugs: Recent History and Next Steps* (with Christen Linke Young & Richard G. Frank), BROOKINGS (July 9, 2025), <https://www.brookings.edu/articles/international-reference-pricing-for-prescription-drugs/>.

*Analyzing the Expansion of the Medicare Drug Price Negotiation Program to Part B* (with Richard G. Frank), BROOKINGS (April 1, 2025), <https://www.brookings.edu/articles/articulating-policy-options-regarding-implementation-of-the-medicare-drug-price-negotiation-programs-renegotiation-provision/>.

*Articulating Policy Options Regarding Implementation of the Medicare Drug Price Negotiation Program's Renegotiation Provision* (with Richard G. Frank), BROOKINGS (Jan. 29, 2025), <https://www.brookings.edu/articles/articulating-policy-options-regarding-implementation-of-the-medicare-drug-price-negotiation-programs-renegotiation-provision/>.

*The FDA Could Do More to Promote Generic Competition: Here's How* (with Marta Wosinska, Richard G. Frank, & Loren Adler & Paul B. Ginsburg), BROOKINGS (June 14, 2022), <https://www.brookings.edu/essay/the-fda-could-do-more-to-promote-generic-competition-heres-how/>.

*A Framework for Categorizing and Analyzing Prescription Drug Pricing Reform Options* (with Loren Adler & Paul B. Ginsburg), BROOKINGS (Aug. 31, 2021), <https://www.brookings.edu/essay/a-framework-for-categorizing-and-analyzing-prescription-drug-pricing-reform-options/>.

*The Drug That Could Break American Health Care* (with Nicholas Bagley), THE ATLANTIC (June 11, 2021), <https://www.theatlantic.com/ideas/archive/2021/06/aduhelm-drug-alzheimers-cost-medicare/619169/>.

*Update on Regulatory Withdrawals of Drug Pricing Rules* (with Bridget C.E. Dooling), NOTICE & COMMENT (March 19, 2021), [https://www.yalejreg.com/nc/update\\_on\\_regulatory\\_withdrawals/](https://www.yalejreg.com/nc/update_on_regulatory_withdrawals/).

*Prescription Drug Affordability: A Bipartisan Goal?*, HUMAN RIGHTS (Sept. 8, 2020), [https://www.americanbar.org/groups/crsj/publications/human\\_rights\\_magazine\\_home/health-matters-in-elections/prescription-drug-affordability/](https://www.americanbar.org/groups/crsj/publications/human_rights_magazine_home/health-matters-in-elections/prescription-drug-affordability/).

*Prescription Drug Affordability*, THE REGULATORY REVIEW (April 30, 2019), <https://www.thereview.org/2019/04/30/sachs-prescription-drug-affordability/>.

*Drug Prices: Where Do We Go After the Election?*, THE CONVERSATION (Oct. 30, 2016), <https://theconversation.com/drug-prices-where-do-we-go-after-the-election-67812>.

- This piece was reprinted in a number of other media outlets, including in *Scientific American*.

*Pharmaceutical Transparency Bills: Targeting Disclosure Purposefully*, THE HASTINGS CENTER BIOETHICS FORUM (April 15, 2016), <http://www.thehastingscenter.org/Bioethicsforum/Post.aspx?id=7844&blogid=140>.

*Happy About the Supreme Court's ACA Decision? Thank a Law Professor*, THE CONVERSATION (June 26, 2015), <https://theconversation.com/happy-about-the-supreme-courts-aca-decision-thank-a-law-professor-43889>.

*How Law Professors Helped the Supreme Court Understand the Affordable Care Act*, THE CONVERSATION (June 16, 2015), <https://theconversation.com/how-law-professors-helped-the-supreme-court-understand-the-affordable-care-act-39982>.

*FDA Proposal for Regulating Laboratory Diagnostics Could Improve Patient Care*, THE HASTINGS CENTER BIOETHICS FORUM (Sept. 4, 2014), <http://www.thehastingscenter.org/Bioethicsforum/Post.aspx?id=7018&blogid=140>.

## GRANTS

Principal Investigator, “State Medicaid Programs and the FDA’s Accelerated Approval Pathway” (Arnold Ventures, 2020-2023)

Co-Investigator (project led by the Brookings Institution Schaeffer Initiative on Health Policy), “Addressing Drug Market and Regulatory Failures” (Arnold Ventures, 2022-present)

## ADDITIONAL PROFESSIONAL EXPERIENCE

**Gibson, Dunn & Crutcher**, Palo Alto, CA

*Summer Associate*, Summer 2012

Drafted legal memoranda and other documents primarily related to intellectual property law.

**Duke University, Program on Global Health and Technology Access**, Durham, NC

*Associate in Research*, 2009–2010

Wrote a strategy paper for the United Nations Development Programme. Researched patent pools for neglected tropical diseases. Helped manage the Program’s extensive portfolio of grants. Organized the Global Health Fellows Program for graduate students, which featured a health policy internship and intensive course.

## SELECTED ACADEMIC AND PROFESSIONAL SERVICE

Washington University School of Law:

- Appointments Committee, 2018 — 2019 (entry-level), spring 2022 (lateral), fall 2022 (combined), spring 2025 (combined), 2025 — 2026 (chair, combined)
- Clerkship Committee, 2016 — 2018, spring 2020 — 2021
- Commencement “Voice of the Faculty” (elected by students), 2022
- Curriculum Committee, 2026 – 2027
- Health Law Society Faculty Advisor, 2022 — present
- Law Review Board of Advisors, 2026 – present
- Promotion & Tenure Committee, 2021 — 2022

Washington University in St. Louis:

- Global Health Visiting Speaker Series Committee, 2018 — 2020
- Faculty Committee on Technology Transfer, 2019 — 2021
- Internal Grant Review Committees, 2020 (Colors of COVID Initiative), 2022 (Office of Vice Chancellor for Research)
- Strategic Planning: Committee on the Research Enterprise, 2021 — 2022
- Strategic Planning: Public Health Implementation, 2022 — 2023
- Center for Advancing Health Services, Policy & Economics Research, Internal Advisory Board, 2024 — present
- Cordell Institute for Policy in Medicine and Law, Faculty Co-Director, 2026 — present

Regulation and Innovation in the Biosciences Junior Scholars Workshop, Steering Committee, 2017 — 2023  
Seasoned Regulation and Innovation in the Biosciences Workshop, Steering Committee, 2024 — present

Journal of Health Policy, Politics, & Law, Editorial Board Member, 2021 — Present

Health Affairs Scholar, Editorial Board Member, 2022 — Present

Institute for Clinical and Economic Review

- Member, Midwest Comparative Effectiveness Public Advisory Council, 2016 — 2026
- Chair, Midwest Comparative Effectiveness Public Advisory Council, 2026 — present

West Health, Member, Council for Informed Drug Spending Analysis, 2020 — 2022

Illinois Governor's Advisory Council on Financing and Access to Sickle Cell Disease Treatment and Other High-Cost Drugs and Treatment, 2024

Health Affairs IRA Observatory, Member, 2025 — present